23 mayo 2017 año - Pembrolizumab Approved
Descripción:
FDA approved Pembrolizumab for specific tumors which have been identified to have a biomarker referred to as microsatellite instability-high. Meant for those who have undergone other treatments, and with no other alternatives.
Añadido al timeline:
fecha:
23 mayo 2017 año
Ahora mismo
~ 8 years and 4 months ago